Shots:
- Bolt to receive $5M up front in cash & $10M as an equity investment. Both companies will receive milestones & royalties on the development & commercialization of products in each other’s territories
- Innovent gets rights to all 3 programs in Greater China & holds an option to get WW license rights for 1 program & rights to all countries for other programs (Ex- NAM). Bolt retains an option to get WW license rights (Ex- Greater China) for 1 program & NAM rights for other programs
- Innovent will lead all R&D costs via POC. The companies can exercise licensing options for continued development & exclusive commercialization rights in countries on a program basis, following a review of POC data
Click here to read full press release/ article | Ref: PR Newswire | Image: MediCircle
The post Innovent Collaborates with Bolt to Develop Three Oncology Boltbody ISAC Programs first appeared on PharmaShots.